Full Text View
Tabular View
No Study Results Posted
Related Studies
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon (TAKEDA)
This study is ongoing, but not recruiting participants.
Study NCT00642694   Information provided by University of Texas Southwestern Medical Center
First Received: March 19, 2008   Last Updated: November 2, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depressive Disorder
Insomnia
Additional conditions recognized in this trial
Depression
Depressive Disorder
Depressive Disorder, Major
Disease
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Pathologic Processes
Interventions listed in this trial
Escitalopram + Ramelteon
Escitalopram + Placebo
Additional drug interventions recognized in this trial
Citalopram
Dexetimide
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Texas Southwestern Medical Center
Takeda Pharmaceuticals North America, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services